Approved medicines Human studies in product label Hormone research
Also discussed as: Sandostatin, Sandostatin LAR
What it is and how it works
Octreotide mimics several actions of somatostatin, including inhibition of growth hormone and other hormone secretions. This is an important counterexample to the idea that peptide therapy always increases a hormone: some peptide medicines suppress signaling in specific diseases.
Source for the mechanism context →A closer look at the cited evidence
Human studies in product label
This label describes the selected source below. It is not a complete ranking of the literature, a safety score, or an approval status.
- Study or assessment
- DailyMed — Sandostatin Injection clinical studies and mechanism
- Design
- Clinical evidence described for the injection’s individual indications.
- Who or what was studied
- Patients with acromegaly or symptoms related to particular hormone-secreting tumors.
- What was observed
- The label describes hormone suppression and control of certain disease-related symptoms.
- Limits of interpretation
- Evidence for these diagnoses is not evidence for general hormone optimization. The injection and depot formulations have different labeling.
What the evidence means
The cited injection label addresses hormone levels and symptoms in specific endocrine and tumor-related conditions.
Approval and regulatory context
Sandostatin Injection has approved indications involving acromegaly and symptoms from particular hormone-secreting tumors. Different formulations have distinct criteria.
Safety and uncertainty
Gallbladder effects, blood-glucose changes, and cardiac effects appear in the label. This is a specialist medicine, not a general hormone-balancing product.
What remains uncertain
The direction of a hormonal change is not, by itself, good or bad. Its clinical meaning depends on the diagnosis and the person’s medical context, which cannot be determined from an educational profile.
These summaries are introductory and are not a complete account of the literature, adverse effects, contraindications, or interactions. Absence of a listed risk does not mean absence of risk. Different compounds, formulations, and routes cannot be treated as interchangeable.
Sources behind this overview
Read the source in its full context. Source links support the overview; they do not imply endorsement of this library by the source organization.
